Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where William H. Foege is active.

Publication


Featured researches published by William H. Foege.


American Journal of Preventive Medicine | 2000

Guide to Community Preventive Services: harnessing the science.

J.Michael McGinnis; William H. Foege

This article presents reactions in the development of the Guide to Community Preventive Services, which brings public health to the same level of scientific scrutiny with evidence-based recommendations for community prevention services. The first reaction found this development a good change that should be supported, encouraged, and continued. It would help health providers know which practices are based on some level of evidence and which practices warrant more study. The second reaction welcomed the development as a step in the institutionalization of public health, subsequently developing public health systems, standardizing the training of public health workers, and incorporating epidemiology in public health practice. In addition, it is noted that the Guide aggregates the experiences of those who have tried and documented preventive practices. In the third reaction, it is viewed that the Guide would point the way to those activities for which additional attention and study is needed. The fourth reaction indicated that the guidelines would further improve collective knowledge. Finally, the fifth reaction stated that this publication would provide local health departments with an abundance of clear and factual information to plan activities, and educate the community.


JAMA | 2015

The President’s National Security Agenda: Curtailing Ebola, Safeguarding the Future

Lawrence O. Gostin; Henry A. Waxman; William H. Foege

A clear lesson of the Ebola epidemic in West Africa is the need for strong public health systems globally, including in the United States. Ebola has highlighted the dangers of weak public health systems, from the immense shortage of health workers in West Africa to the budget cuts at the U.S. Centers for Disease Control and Prevention. In response to Ebola and the broader threat of infectious disease, President Obama has proposed a


Vaccine | 2011

Lessons and innovations from the West and Central African Smallpox Eradication Program.

William H. Foege

6.2 billion supplemental funding request to Congress. The supplemental would surge resources for containing and treating Ebola in West Africa -- including a reserve of funds to enable a robust, flexible response going forward -- enhance prevention and detection of, and response to, Ebola in the United States, and buttress U.S. and partner country health systems to respond rapidly and flexibly to all infectious disease hazards in the future. The additional resources the supplemental would devote to the ongoing Ebola crisis is critically important. So is the supplemental requests funding to prepare for the future, including developing treatment centers in the United States that would provide advanced care and isolation facilities, and funding for research and development for vaccines and medicines for Ebola and other novel infections. The request would also provide the first significant batch of funding to the Global Health Security Agenda, which President Obama unveiled in February 2014. The Global Health Security Agenda takes an all-hazards approach to building greater global capacity to prevent, detect, and respond to infectious diseases, from zoonotic diseases and antibiotic resistant bacteria to biosecurity and bioterror threats. From environmental degradation to increased human-animal interchange, the threats are only increasing. Strong public health systems at home and globally are our best defense. Congress should support the Presidents supplemental funding request, furthering a bipartisan U.S. tradition of support for global health, continuing U.S. global leadership in the Ebola response, and preparing our country and our world for disease threats of the future.


JAMA | 1972

Discontinuance of Routine Smallpox Vaccination

William H. Foege

In 1966, the Centers for Disease Control began training medical officers and public health advisors for a program that would encompass 20 countries of West and Central Africa with the objective of eradicating smallpox and controlling measles. The program was funded by the US Agency for International Development with a target of smallpox eradication within 5 years and the immunization of children from 6 months to 6 years of age against measles in all areas of every country. The 40 plus field staff were directed by a Regional Office in Lagos, Nigeria and a headquarters group in Atlanta, Georgia. The teams greatly expanded the knowledge of smallpox epidemiology, helped to expand the capabilities of Ministries of Health, pioneered the use of jet injectors to provide millions of immunizations, and expanded the use of surveillance/containment to become a primary strategy for interrupting smallpox transmission. Smallpox transmission was interrupted in three and one half years, a year and a half before the time targeted and under budget. Measles transmission was interrupted in one country, The Gambia, and significantly reduced in the other 19 countries.


JAMA | 1993

Actual causes of death in the United States.

J. Michael McGinnis; William H. Foege

To the Editor.— The immunity status of the US population by age and geographic area is well known from previous immunization surveys. However, a study of European importations and control efforts in west Africa have shown that population immunity is not the single most important factor in determining whether an importation spreads widely. Instead, the important factors appear to be the specific population immunity in the hospital admitting the patient, the speed with which smallpox is recognized, and appropriate control procedures. The administration of attenuated smallpox vaccine or killed vaccine prior to smallpox vaccination cannot be recommended at this time. While it is known that attenuated vaccines can reduce fever and local reactions at the time of vaccination, information is not available regarding life-threatening complication rates with attenuated vaccine. Also, there is no information concerning the protective effect of attenuated vaccine alone or followed by calf lymph vaccine against smallpox


JAMA | 1997

Public Health and Preventive Medicine

William H. Foege


Proceedings of the Association of American Physicians | 1999

Mortality and morbidity attributable to use of addictive substances in the United States.

J. M. McGinnis; William H. Foege


JAMA | 1991

Preventive Medicine and Public Health

William H. Foege


JAMA | 2004

The Immediate vs the Important

J. Michael McGinnis; William H. Foege


JAMA | 1985

Closing the Gap: Report of The Carter Center Health Policy Consultation

William H. Foege; Robert W. Amler; Craig C. White

Collaboration


Dive into the William H. Foege's collaboration.

Top Co-Authors

Avatar

Annette Flanagin

American Medical Association

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

J. Michael McGinnis

Robert Wood Johnson Foundation

View shared research outputs
Top Co-Authors

Avatar

William W. McLendon

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

J. M. McGinnis

National Academy of Sciences

View shared research outputs
Top Co-Authors

Avatar

Lawrence O. Gostin

Georgetown University Law Center

View shared research outputs
Top Co-Authors

Avatar

Robert W. Amler

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge